Novavax is trading at $11.69, down 6.92%, with no clear new company-specific catalyst reported for the October 6 decline. - It is giving back part of its 20.08% rise to $12.56 on October 5. Coverage linked Monday’s rally to a Russian lab-worker death, infectious-disease speculation and positive vaccine-sector sentiment. - The WHO assessed public risk as low; Novavax has no plague vaccine. - XBI is down 2.50%, while major indexes are higher; no broad-market explanation is evident.